Janus Henderson Group PLC Viracta Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.37 - $7.91 $841,441 - $1.98 Million	-249,686 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$7.84 - $12.53 $500,858 - $800,479	-63,885 Reduced 20.37%	249,686 $2 Million
Q2 2021 Aug 16, 2021	SELL	$7.55 - $12.95 $2.52 Million - $4.32 Million	-333,249 Reduced 51.52%	313,571 $3.55 Million
Q1 2021 May 17, 2021	BUY	$7.58 - $18.67 $4.9 Million - $12.1 Million	646,820 New	646,820 $5.99 Million

3.66M

1.8K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $1.13M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.